Prediction of chemotherapy-mediated cardiotoxicity in patients with cancer by cardiac troponin I: A systematic review and meta-analysis

Abstract

Background

Cardiac damage is a significant risk of chemotherapy. Elevated circulating cardiac troponin I was suggested as a marker for early detection of cardiac damage.

Objective

We aim to assess the predictive value of cardiac troponin I for chemotherapy-induced cardiotoxicity in cancer patients.

Methods

We searched PubMed, Web of Science, Embase, and CNKI. Nine prospective studies involving 2033 cancer patients (pts) were included in the meta-analysis. Troponin I (TnI) levels in patients who underwent chemotherapy were categorized into cardiac troponin I (cTnI) positive and negative groups based on the cutoff concentrations described in the included studies. The cumulative effects of chemotherapy-induced cardiotoxicity between the cTnI-positive and cTnI-negative patients were represented as a summarized risk difference (RD) value with a 95% confidence interval. Subgroup analysis and sensitivity analysis were employed to address heterogeneities. Stata software (version 12.0) was utilized for the analysis.

Results

cTnI-positive pts represented significant cardiotoxicity compared to cTnI-negative pts, as a decline in left ventricular ejection fraction (LVEF): RD = 0.279 [95% CI (0.248–0.311), p = 0.000, I² = 81.3%, 8 trials], heart failure (HF): RD = 0.117, [95% CI (0.090–0.144), p = 0.000, I² = 77.8%, 6 trials], arrhythmias: RD = 0.057 [95% CI (0.028–0.086), p = 0.000, I² = 0.0%, 3 trials], and cumulative events: RD = 0.318 [95% CI (0.272–0.364), p = 0.000, I² = 73.5%, 3 trials]. No statistically significant difference in cardiac death, acute pulmonary edema, and acute coronary syndromes between cTnI-positive pts and cTnI-negative pts was identified.

Conclusions

An increase in circulating troponin I serve as a potential biomarker that reflecting the high risk of early cardiotoxicity in cancer patients who have undergone chemotherapy. The presence of intrinsic unadjusted confounding factors in the reports suggests the need for further study to address this question.

Keywords

chemotherapy troponin I cardiotoxicity left ventricular fraction ejection heart failure cancer

Get full access to this article

View all access options for this article.

References

Yeh

Chang

. Oncocardiology-past, present, and future: a review. JAMA Cardiol 2016; 1(9): 1066–1072.

Thigpen

Geraci

. Prediction of anthracycline-induced left ventricular dysfunction by cardiac troponins. South Med J 2012; 105(12): 659–664.

Curigliano

Cardinale

Dent

, et al. Cardiotoxicity of anticancer treatments: epidemiology, detection, and management. CA Cancer J Clin 2016; 66(4): 309–325.

Willis

Parry

Brown

, et al. Doxorubicin exposure causes subacute cardiac atrophy dependent on the striated muscle–specific ubiquitin ligase MuRF1. Circ Heart Fail 2019; 12: e005234.

Lotrionte

Biondi-Zoccai

Abbate

, et al. Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity. Am J Cardiol 2013; 112(12): 1980–1984.

Pinder

Duan

Goodwin

, et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 2007; 25(25): 3808–3815.

Cardinale

Colombo

Bacchiani

, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 2015; 131(22): 1981–1988.

Dempke

WCM

Zielinski

Winkler

, et al.

Anthracycline-induced cardiotoxicity - are we about to clear this hurdle?

Eur J Cancer 2023; 185: 94–104.

Gavila

Seguí

MÁ

Calvo

, et al. Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study. Clin Transl Oncol 2017; 19(1): 91–104.

10.

Srikanthan

Klug

Tirona

, et al. Creating a biomarker panel for early detection of chemotherapy related cardiac dysfunction in breast cancer patients. J Clin Exp Cardiol 2017; 8(3): 507.

11.

Bose

Jain

Kawthekar

, et al. The importance of serial time point quantitative assessment of cardiac Troponin I in the diagnosis of acute myocardial damage. Indian J Crit Care Med 2018; 22(9): 629–631.

12.

Gohar

Chong

JPC

Liew

, et al. The prognostic value of highly sensitive cardiac troponin assays for adverse events in men and women with stable heart failure and a preserved vs. reduced ejection fraction. Eur J Heart Fail 2017; 19(12): 1638–1647.

13.

Cardinale

Sandri

. Role of biomarkers in chemotherapy-induced cardiotoxicity. Prog Cardiovasc Dis 2010; 53(2): 121–129.

14.

Battisha

Sawalha

Obeidat

, et al. Role of cardiac biomarkers in monitoring cardiotoxicity in chemotherapy patients. Crit Pathw Cardiol 2023; 22(3): 83–87.

15.

Cardinale

Cipolla

. Assessment of cardiotoxicity with cardiac biomarkers in cancer patients. Herz 2011; 36(4): 325–332.

16.

Page

McKenzie

Bossuyt

, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71.

17.

Stang

. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25(9): 603–605.

18.

Wells

Shea

O'Connell

, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp

19.

Higgins

Thompson

Deeks

, et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327(7414): 557–560.

20.

Egger

Davey Smith

Schneider

, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315(7109): 629–634.

21.

Cardinale

Sandri

Martinoni

, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 2000; 36(2): 517–522.

22.

Cardinale

Sandri

Martinoni

, et al. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol 2002; 13(5): 710–715.

23.

Sandri

Cardinale

Zorzino

, et al. Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy. Clin Chem 2003; 49(2): 248–252.

24.

Cardinale

Sandri

Colombo

, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004; 109(22): 2749–2754.

25.

Cardinale

Colombo

Torrisi

, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 2010; 28(25): 3910–3916.

26.

Huang

Yao

Liu

, et al. Value of cardiac troponin I measurement in prediction of anthracycline-induced cardiotoxicity in breast cancer patients. Nan Fang Yi Ke Da Xue Xue Bao 2011; 31(6): 1047–1050, Chinese.

27.

Yuejiu

Sen

. Value of cardiac troponin I (CTnI) measurement in prediction of anthracycline (ANT)-induced cardiotoxicity. Contemporary Medicine 2012; 18(25): 23–24. DOI: 10.3969/j.issn.1009-4393.2012.25.012.

28.

Shafi

Siddiqui

Imtiaz

, et al. Left ventricular systolic dysfunction predicted by early Troponin I release after anthracycline based chemotherapy in breast cancer patients. J Ayub Med Coll Abbottabad 2017; 29(2): 266–269.

29.

Jin-long

JIANG

Cheng-fu

Guang-sheng

. Clinical value of high sensitive cardiac troponin - in monitoring cardiac toxicity in patients treated with anthracycline. Chin J Cardiovasc Rehabil Med 2018; 27(5): 537–541. DOI: 10.3969/j.issn.1008-0074.2018.05.12.

30.

Mahajan

Jarolim

. How to interpret elevated cardiac troponin levels. Circulation 2011; 124(21): 2350–2354.

31.

Polena

Shikara

Naik

, et al. Troponin I as a marker of doxorubicin induced cardiotoxicity. Proc West Pharmacol Soc 2005; 48: 142–144.

32.

Romano

Fratini

Ricevuto

, et al. Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients. Br J Cancer 2011; 105(11): 1663–1668.

33.

Zaja

Tomadini

Zaccaria

, et al. CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2006; 47(10): 2174–2180.

34.

Sterne

. Investigating and dealing with publication and other biases. In: Egger

Smith

(eds). Systematic Reviews in Health Care. London, UK: BMJ Books, 2001, pp. 189–205.

35.

Serne

Egger

Smith

. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ 2001; 323: 101–105.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.24 MB